1. Home
  2. WGSWW vs TLF Comparison

WGSWW vs TLF Comparison

Compare WGSWW & TLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WGSWW
  • TLF
  • Stock Information
  • Founded
  • WGSWW 2017
  • TLF 1980
  • Country
  • WGSWW United States
  • TLF United States
  • Employees
  • WGSWW 1000
  • TLF N/A
  • Industry
  • WGSWW Retail: Computer Software & Peripheral Equipment
  • TLF Apparel
  • Sector
  • WGSWW Technology
  • TLF Consumer Discretionary
  • Exchange
  • WGSWW Nasdaq
  • TLF Nasdaq
  • Market Cap
  • WGSWW N/A
  • TLF N/A
  • IPO Year
  • WGSWW N/A
  • TLF N/A
  • Fundamental
  • Price
  • WGSWW $0.06
  • TLF $3.46
  • Analyst Decision
  • WGSWW
  • TLF
  • Analyst Count
  • WGSWW 0
  • TLF 0
  • Target Price
  • WGSWW N/A
  • TLF N/A
  • AVG Volume (30 Days)
  • WGSWW 36.6K
  • TLF 14.3K
  • Earning Date
  • WGSWW 02-18-2025
  • TLF 08-06-2025
  • Dividend Yield
  • WGSWW N/A
  • TLF 43.35%
  • EPS Growth
  • WGSWW N/A
  • TLF 241.69
  • EPS
  • WGSWW N/A
  • TLF 1.47
  • Revenue
  • WGSWW $305,450,000.00
  • TLF $74,152,000.00
  • Revenue This Year
  • WGSWW N/A
  • TLF N/A
  • Revenue Next Year
  • WGSWW N/A
  • TLF N/A
  • P/E Ratio
  • WGSWW N/A
  • TLF $2.37
  • Revenue Growth
  • WGSWW 50.79
  • TLF N/A
  • 52 Week Low
  • WGSWW $0.17
  • TLF $2.69
  • 52 Week High
  • WGSWW $0.21
  • TLF $5.48
  • Technical
  • Relative Strength Index (RSI)
  • WGSWW N/A
  • TLF 65.04
  • Support Level
  • WGSWW N/A
  • TLF $3.29
  • Resistance Level
  • WGSWW N/A
  • TLF $3.59
  • Average True Range (ATR)
  • WGSWW 0.00
  • TLF 0.14
  • MACD
  • WGSWW 0.00
  • TLF 0.02
  • Stochastic Oscillator
  • WGSWW 0.00
  • TLF 73.47

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Share on Social Networks: